Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?

Expert Opin Pharmacother. 2022 Nov;23(16):1761-1764. doi: 10.1080/14656566.2022.2141567. Epub 2022 Nov 10.

Authors

Dominika Kabiesz^{1

2}, Piotr Smolewski¹

Affiliations

¹ Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland.
² Department of Hematology, Copernicus Memorial Hospital, Lodz, Poland.

PMID: 36366875
DOI: 10.1080/14656566.2022.2141567

No abstract available

Keywords: Aggressive B-cell lymphoma; biologically targeted agents; immunochemotherapy; standard-of-care treatment.

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Rituximab / therapeutic use

Substances

Rituximab